YH001, a monoclonal antibody targeting CTLA-4, can improve the body’s immune response to tumor cells and enhance the removal of Regulatory T cells (Treg cells) in the tumor microenvironment, making it an attractive therapeutic agent for treating a variety of tumors. It is considered to be the most promising tumor immunotherapy to enhance patients’ immune response to tumors by blocking an inhibitory signal of human anti-tumor responses. The R & D team redesigned their approach to developing CTLA-4 antibodies and discovered YH001 using the “gold standard” in vivo efficacy screening in syngeneic tumor models. In preclinical studies, YH001 showed extremely high affinity and excellent safety performance, and has demonstrated promising potential in combination with other drugs in animal efficacy experiments.
In May 2020, the Phase I clinical trial of YH001 and anti-PD-1 mAb (Toripalimab Injection, Junshi Biosciences) combination therapy was officially launched in Australia. In 2021, the first patient screening was completed for YH001 Phase I trials in China. In June 2021, YH001 was approved to enter phase II trials by the FDA.